Scaling protein production and kinetics by 100x to advance disease biology, AI-driven drug design, and therapy development.

Scaling protein production and kinetics by 100x to advance disease biology, AI-driven drug design, and therapy development.

The Challenges of Proteins Study

Current recombinant protein workflows for producing and studying protein kinetics are complex, time-consuming, and expensive. This presents a significant barrier to understanding the causes of diseases, as well as achieving early detection and cure.

SPOC Platform: Protein Nano Factory and High Plex Kinetics

A transformative technology that produces 1000s of full-length folded proteins on a biosensor chip, enabling the evaluation of protein binding kinetics at just 10% of the current cost. This innovative approach is set to revolutionize AI drug design, pre-clinical drug development, vaccines, protein biomarker discovery for precision medicine and diagnostics.

Our Transformative Technology

We are developing a transformative technology that produces thousands of proteins on a biosensor chip, enabling simultaneous real-time biosensing of thousands of protein bindings and interactions at just 10% of the current cost. This groundbreaking approach also promises to revolutionize pre-clinical drug discovery and wet lab testing of AI-designed drug molecules.

Understanding Our Genetic Blueprint.

  • Unveiling the secrets of the proteome.

  • Unveiling the secrets of the proteome.

Fast-Tracking Therapies

Fast-Tracking Therapies

SPOC is designed to generate proteomic interaction data at 100x the scale and depth, compared to current workflows. SPR kinetic screening facilitates resolving drug bindings with micro-molar to pico-molar kinetic affinities, not feasible with phage and yeast display methods. In near future, SPOC MALDI mass spec screening will output million data points in a single assay.

SPOC is designed to generate proteomic interaction data at 100x the scale and depth, compared to current workflows. SPR kinetic screening facilitates resolving drug bindings with micro-molar to pico-molar kinetic affinities, not feasible with phage and yeast display methods. In near future, SPOC MALDI mass spec screening will output million data points in a single assay.

Unlocking the power of AI drug design

Unlocking the power of AI drug design

In silico designed drug molecules require wet lab testing to validate binding to their protein targets, generate objective data to select and develop promising drug candidates. Training data for AI models is limited. Large-scale, deep characterization datasets on drug-protein binding kinetics are needed to enhance AI model accuracies.

In silico designed drug molecules require wet lab testing to validate binding to their protein targets, generate objective data to select and develop promising drug candidates. Training data for AI models is limited. Large-scale, deep characterization datasets on drug-protein binding kinetics are needed to enhance AI model accuracies.

Accelerating development of best-in-class drugs

Accelerating development of best-in-class drugs

High binding affinities are preferred for monoclonal antibody (mAb) drugs (e.g., Keytruda, Humira), while moderate affinities are optimal for CAR-Ts and BiTEs to prevent T cell exhaustion. In contrast, ADC modalities require tailored optimization of kinetic parameters to minimize dose-limiting off-target toxicities.

High binding affinities are preferred for monoclonal antibody (mAb) drugs (e.g., Keytruda, Humira), while moderate affinities are optimal for CAR-Ts and BiTEs to prevent T cell exhaustion. In contrast, ADC modalities require tailored optimization of kinetic parameters to minimize dose-limiting off-target toxicities.

Our vision is to produce and supply protein biosensor chips globally, to democratize proteomics and help resolve the complex proteome.

Our vision is to produce and supply protein biosensor chips globally, to democratize proteomics and help resolve the complex proteome.

For more information on the SPOC platform, get in touch:

Contact Us

Privacy & Conditions

1600 Adams Drive Suite236

Menlo Park, CA 94025

7201 E Henkel Way, Suite 285 Scottsdale, AZ 85255

480-219-9506

All rights reserved © 2024

For more information on the SPOC platform, get in touch:

Contact Us

Privacy & Conditions

1600 Adams Drive Suite236

Menlo Park, CA 94025

7201 E Henkel Way, Suite 285 Scottsdale, AZ 85255

480-219-9506

All rights reserved © 2024

Join us in transforming healthcare through the power of proteomics

Join us in transforming healthcare through the power of proteomics

Product Brochure

Product Brochure

Preprint Publication

Preprint Publication

For more information on the SPOC platform, get in touch:

Contact Us

1600 Adams Drive

Suite236



Menlo Park, CA 94025

7201 E Henkel Way

Suite 285



Scottsdale, AZ 85255

480-219-9506

Privacy & Conditions

All rights reserved © 2024